An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

NCT03351231 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Inability to meet protocol objectives

Conditions

Cancer

Interventions

DRUG: BMS-986242
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb